Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects

BACKGROUND: The novel iron-based phosphate binder sucroferric oxyhydroxide is being investigated for the treatment of hyperphosphatemia. Patients with chronic kidney disease often have multiple comorbidities that may necessitate the daily use of several types of medication. Therefore, the potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Edward, Kalia, Veena, Willsie, Sandra, Winkle, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242982/
https://www.ncbi.nlm.nih.gov/pubmed/24699894
http://dx.doi.org/10.1007/s40620-014-0080-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242982/
https://www.ncbi.nlm.nih.gov/pubmed/24699894
http://dx.doi.org/10.1007/s40620-014-0080-1

Ejemplares similares